Skip to content
BiologicalX

Comparison

GHK-Cu vs Modafinil

Side-by-side of GHK-Cu and Modafinil. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

GHK-Cu

  • Endogenous tripeptide that binds copper(II); plasma levels decline ~60% from age 20 to 60
  • Topical RCTs show improvement in skin firmness, fine lines, and barrier function over 12 weeks
  • Wound-healing models report accelerated re-epithelialization in diabetic and aged skin
  • Pickart gene-expression analyses show reset of >4000 genes toward a younger expression profile in cell culture
  • Anecdotal subcutaneous longevity protocols use 1 to 3 mg daily; no human longevity RCTs exist
  • Hair-growth claims rest on small open-label trials and topical scalp formulations

Modafinil

  • FDA approved in 1998 for narcolepsy, with later additions for shift-work sleep disorder and OSA residual sleepiness
  • Schedule IV controlled substance in the US; prescription-only in EU, UK, Australia
  • Increases wakefulness via weak dopamine reuptake inhibition plus histaminergic, noradrenergic, and orexinergic activation
  • Long half-life of 12 to 15 hours requires morning dosing to avoid sleep disruption
  • Modest cognitive enhancement signal in non-sleep-deprived adults at 100 to 200 mg (Battleday meta-review 2015)
  • Substantial CYP3A4 induction reduces hormonal contraceptive efficacy; barrier methods recommended

Side-by-side

Attribute GHK-Cu Modafinil
Category peptide pharmaceutical
Also known as Copper Peptide, Glycyl-L-histidyl-L-lysine copper, GHK Provigil, Modalert, Modvigil, diphenylmethylsulfinyl-acetamide
Half-life (hr) 0.5 13
Typical dose (mg) 2 200
Dosing frequency daily daily, morning
Routes topical, subcutaneous oral
Onset (hr) 24 1
Peak (hr) 168 3
Molecular weight 340.85 273.35
Molecular formula C14H24N6O4 (GHK alone); C14H22CuN6O4 with Cu(II) C15H15NO2S
Mechanism Tripeptide that chelates Cu(II) and delivers it to copper-dependent enzymes (lysyl oxidase, superoxide dismutase). Modulates expression of >4000 genes toward a younger profile in fibroblast culture, including upregulation of decorin and downregulation of pro-inflammatory cytokines. Weak dopamine reuptake inhibition plus downstream activation of histaminergic, noradrenergic, and orexinergic wake-promoting systems.
Legal status Topical cosmetics legal in most jurisdictions; injectable form not FDA approved for any indication; research-use-only grey market Schedule IV (US); prescription-only globally; not a supplement
WADA status allowed banned
DEA / Rx Topical OTC (cosmetic); injectable not FDA approved; research-chemical status Schedule IV
Pregnancy Insufficient data; topical use likely low-risk; injectable not recommended Not recommended
CAS 49557-75-7 68693-11-8
PubChem CID 73587 4236
Wikidata Q3104638 Q422968

Safety profile

GHK-Cu

Common side effects

  • mild erythema at topical site
  • transient itch
  • blue-green discoloration of injection site (copper)
  • rare contact dermatitis

Contraindications

  • copper allergy
  • Wilson disease
  • open wound near injection site (caution)
  • pregnancy (no data)

Interactions

  • topical retinoids: additive irritation; alternate days or apply at different times(minor)
  • topical vitamin C (ascorbic acid): ascorbate reduces Cu(II) to Cu(I), which can destabilize the GHK-Cu complex; separate by 30 minutes(minor)

Modafinil

Common side effects

  • headache
  • nausea
  • anxiety
  • insomnia (with late-day dosing)
  • dry mouth
  • mild blood pressure elevation

Contraindications

  • recent myocardial infarction
  • unstable angina
  • left ventricular hypertrophy
  • significant arrhythmia
  • history of Stevens-Johnson syndrome
  • psychotic disorders
  • pregnancy
  • concurrent MAOI use

Interactions

  • hormonal contraceptives: CYP3A4 induction reduces contraceptive efficacy; use barrier method(major)
  • cyclosporine: reduced cyclosporine levels via CYP3A4 induction(major)
  • warfarin: CYP2C9 inhibition raises INR(moderate)
  • phenytoin: CYP2C19 inhibition raises phenytoin levels(moderate)
  • MAOIs: potential hypertensive reaction(major)
  • classical stimulants (amphetamine, methylphenidate): additive cardiovascular and sleep-disruption effects(moderate)

Which Should You Take?

Modafinil comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. GHK-Cu is the right call when one of the conditionals below applies.

  • If your priority is skin health, pick GHK-Cu.
  • If your priority is wound healing, pick GHK-Cu.
  • If your priority is wakefulness, pick Modafinil.
  • If your priority is focus or working memory, pick Modafinil.

Edge case: If you cannot self-administer injections, Modafinil is the only oral option in this pair.

Default choice: Modafinil. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for GHK-Cu only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between GHK-Cu and Modafinil?

GHK-Cu and Modafinil differ in category (peptide vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, GHK-Cu or Modafinil?

GHK-Cu half-life is 0.5 hours; Modafinil half-life is 13 hours.

Can you stack GHK-Cu with Modafinil?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper